| Autor: |
Constantinides, V.C. Paraskevas, G.P. Boufidou, F. Bourbouli, M. Stefanis, L. Kapaki, E. |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Popis: |
Introduction: Total tau (τT), phosphorylated tau (τP-181) and amyloid beta (Aβ42) are cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD). There is no consensus on the interpretation criteria of these biomarkers. The aim of this study was to apply three different sets of criteria for CSF AD biomarker interpretation in a cohort of corticobasal degeneration (CBD) patients. Method: SForty patients fulfilling diagnostic criteria for “probable CBD” were included. The AT(N), BIOMARKAPD/ABSI and the τP-181/Aβ42 ratio criteria were applied. Results: The AT(N) criteria categorized 50% of “probable CBD” patients as AD, and 62.5% as harboring amyloid pathology. The BIOMARKAPD/ABSI and τP- 181/Aβ42 criteria categorized ~40% of “probable CBD” patients as AD. Discussion: Use of different interpretation criteria for CSF AD biomarkers produces diverse results. AD pathology is common in patients fulfilling “probable” CBD criteria. CBD diagnostic criteria may have suboptimal positive predictive value. A consensus regarding interpretation criteria of CSF AD biomarkers is pivotal. © 2020 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
